Medicenna Therapeutics (TSE:MDNA) Trading Down 1.7% – Here’s What Happened

Medicenna Therapeutics Corp. (TSE:MDNA) shares were down 1.7% during mid-day trading on Monday . The stock traded as low as C$1.06 and last traded at C$1.13. Approximately 72,877 shares traded hands during trading, an increase of 2% from the average daily volume of 71,481 shares. The stock had previously closed at C$1.15.

Medicenna Therapeutics Trading Down 1.7 %

The firm has a market cap of C$84.54 million, a price-to-earnings ratio of -3.11 and a beta of 1.21. The company’s 50-day moving average price is C$1.43 and its 200-day moving average price is C$1.84. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88.

Insider Buying and Selling

In other Medicenna Therapeutics news, Senior Officer David Hyman acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, January 9th. The stock was bought at an average price of C$1.45 per share, with a total value of C$29,000.00. 22.57% of the stock is currently owned by insiders.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.